Trending: Seattle shooting rattles tech leaders and raises concerns about safety of city’s urban core

VLST Corp., a Seattle biotech developing therapeutics for the treatment of autoimmune and inflammatory diseases, has raised an additional $5 million in venture capital financing, according to a SEC filing today. The company could raise another $10 million in the round, according to the filing.

Backers of the company — incubated at the Accelerator Corp. — include OVP Venture Partners, Arch Venture Partners, WRF Capital and others.  Xconomy’s Luke Timmerman notes that the company has raised about $50 million to date, with the new funds to be used to push ahead R&D efforts.

VLST is led by Marty Simonetti, the former CFO at Dendreon Corporation and ex-vice president of operations at at Amgen Inc.

With more than $100 million invested in domain name registrar Donuts; $30 million invested in medical device maker Kona Medical and $18 million invested in SEOMoz in recent weeks, the second quarter is shaping up to be a big one in the venture capital circles in Washington state.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline


Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.